

Technology Appraisal Committee B Interests Register

Topic: Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221

Publication Date: 16 July 2025

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|----------------------|----------------------|----------------------|--|--------------------------|---|
| David McAllister | TAC Committee Member | Indirect - Financial | David's research involves the use of trial data provided by a competitor company (Sanofi) provided via the Vivli trial platform. | 07/05/2025 12/02/2025 | It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal. |
| Peter Wheatley Price | TAC Committee Member | Direct Financial | Takeda have an investigational asset called TAK-279 (oral allosteric tyrosine kinase 2 (TYK2) inhibitor) which is similar to deucravacitinib. TAK 279 is being investigated for Psoriasis, Psoratic Arthritis, Crohn's and UC. Peter does not believe that Takeda are researching atopic dermatitis. | 07/05/2025 25/02/2025 | It was agreed that Peter's declaration would not prevent him from participating in discussions on this appraisal. |
| Mike Chambers | TAC Committee Member | Indirect - Financial | Mike has provided consulting advice to Sanofi (submitting company) not specific to any disease area, and has participated in an advisory panel for Pfizer (possible comparator | 07/05/2025 | It was agreed that Mike's declaration would not prevent him from participating in discussions on this appraisal. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|----------------|-----------------|------------------------|---|-------------------|---|
| | | | company) in an unrelated disease area: prostate cancer | | |
| Dr Philip Laws | Clinical Expert | Direct - Financial | Dr Laws has received honoraria and/or grants as an investigator, speaker, and/or advisory board member for AbbVie, Almirall, Actelion, Celgene, Galderma, Janssen, Lilly, Sanofi, Leo, UCB and Novartis | 07/05/2025 | It was agreed that Dr Laws's declaration would not prevent him from participating in discussions on this appraisal. |
| Andrew Pink | Clinical Expert | Direct – Financial | Acted as investigator, speaker or advisor to Galderma, Sanofi, Leo, Amgen, Abbvie, Lilly, Pfizer, Novartis, BMS, UCB, BI, Janssen Received research funding from Amgen | 07/05/2025 | It was agreed that Mr Pink's declaration would not prevent him from participating in discussions on this appraisal. |
| | | Direct – non-financial | Received educational support from Sanofi, Novartis, Janssen, Abbvie, Leo | 07/05/2025 | It was agreed that Mr Pink's declaration would not prevent him from participating in discussions on this appraisal. |

DRAFT